We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Earnings season is undoubtedly the most critical period for stocks as companies finally unveil what’s transpired behind closed doors.
So far, we’ve received a surplus of quarterly results, including those from technology titans Apple (AAPL - Free Report) , Alphabet (GOOGL - Free Report) , and Microsoft (MSFT - Free Report) .
Now, a big-time player in the Zacks Medical sector, AbbVie (ABBV - Free Report) , is slated to unveil its quarterly results on Thursday, February 9th, before market open.
AbbVie enjoys leadership positions in key therapeutic areas, including immunology, hematologic oncology, neuroscience, aesthetics, eye care, and women’s health.
How does the company currently stack up? We can use quarterly results from a few peers, Eli Lilly (LLY - Free Report) and Merck & Co. (MRK - Free Report) , as a small gauge. Let’s take a closer look.
Eli Lilly Q4
Eli Lilly’s Q4 results were released on February 2nd. LLY reported earnings of $2.09 per share, handily surpassing the $1.83 Zacks Consensus EPS Estimate by roughly 14%.
Quarterly revenue totaled $7.3 billion, marginally falling short of expectations and decreasing nearly 9% from year-ago quarterly sales of $8 billion. Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
In addition, the company’s revenue generated from its COVID-19 antibodies took a sizable hit as the pandemic slowly fades, reported at $38 million and falling 96% year-over-year.
Several large-cap pharmaceutical companies benefitted significantly from their COVID-19 treatments and products, and now we’re seeing this trend reverse.
Merck & Co. Q4
Merck posted better-than-expected results, exceeding the Zacks Consensus EPS Estimate by roughly 4% and reporting earnings of $1.62 per share.
The company generated approximately $13.8 billion in sales, again exceeding our consensus sales estimate modestly and growing 2.2% year-over-year.
Image Source: Zacks Investment Research
In addition, the company provided guidance for FY23; Merck now expects worldwide sales of $57.2 billion – $58.7 billion and full-year GAAP EPS in a range of $5.86 per share – $6.01 per share.
AbbVie
Quarterly Estimates –
Analysts have been bearish in their earnings outlooks, with four negative earnings estimate revisions hitting the tape over the last several months. Still, the Zacks Consensus EPS Estimate of $3.54 suggests an improvement of nearly 7% year-over-year.
Image Source: Zacks Investment Research
The company’s top line is also estimated to expand, with our consensus sales estimate of $15.4 billion indicating an uptick of 3% from year-ago quarterly sales of $14.9 billion.
Quarterly Performance –
The company has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
In AbbVie’s latest print, the company delivered a 3% EPS surprise and reported sales roughly 0.8% below expectations.
Image Source: Zacks Investment Research
Valuation –
ABBV shares currently trade at a 12.4X forward earnings multiple, above the 9.5X five-year median by a fair margin and nearly in line with 2022 highs.
Image Source: Zacks Investment Research
Further, ABBV’s forward price-to-sales works out to be 4.8X, again above the 3.7X five-year median and the Zacks Medical sector average.
Image Source: Zacks Investment Research
ABBV carries a Style Score of “B” for Value.
Putting Everything Together
As the critically-important earnings season continues to roll on, investors have been met with quarterly results that have helped keep the market afloat. Needless to say, the so-called earnings apocalypse has yet to materialize.
Next week, AbbVie (ABBV - Free Report) is slated to unveil its quarterly results on Thursday, February 9th, before market open. We’ve already received quarterly results from a few peers, including Eli Lilly (LLY - Free Report) and Merck & Co. (MRK - Free Report) .
Analysts have lowered their earnings outlooks for AbbVie’s quarter to be reported, with estimates indicating Y/Y increases in earnings and revenue.
In addition, the company’s forward price-to-sales and forward earnings multiple reside well above their respective five-year medians.
Heading into the release, AbbVie is currently a Zacks Rank #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
AbbVie Q4 Preview: What's in Store?
It’s that time of the year – earnings season.
Earnings season is undoubtedly the most critical period for stocks as companies finally unveil what’s transpired behind closed doors.
So far, we’ve received a surplus of quarterly results, including those from technology titans Apple (AAPL - Free Report) , Alphabet (GOOGL - Free Report) , and Microsoft (MSFT - Free Report) .
Now, a big-time player in the Zacks Medical sector, AbbVie (ABBV - Free Report) , is slated to unveil its quarterly results on Thursday, February 9th, before market open.
AbbVie enjoys leadership positions in key therapeutic areas, including immunology, hematologic oncology, neuroscience, aesthetics, eye care, and women’s health.
How does the company currently stack up? We can use quarterly results from a few peers, Eli Lilly (LLY - Free Report) and Merck & Co. (MRK - Free Report) , as a small gauge. Let’s take a closer look.
Eli Lilly Q4
Eli Lilly’s Q4 results were released on February 2nd. LLY reported earnings of $2.09 per share, handily surpassing the $1.83 Zacks Consensus EPS Estimate by roughly 14%.
Quarterly revenue totaled $7.3 billion, marginally falling short of expectations and decreasing nearly 9% from year-ago quarterly sales of $8 billion. Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
In addition, the company’s revenue generated from its COVID-19 antibodies took a sizable hit as the pandemic slowly fades, reported at $38 million and falling 96% year-over-year.
Several large-cap pharmaceutical companies benefitted significantly from their COVID-19 treatments and products, and now we’re seeing this trend reverse.
Merck & Co. Q4
Merck posted better-than-expected results, exceeding the Zacks Consensus EPS Estimate by roughly 4% and reporting earnings of $1.62 per share.
The company generated approximately $13.8 billion in sales, again exceeding our consensus sales estimate modestly and growing 2.2% year-over-year.
Image Source: Zacks Investment Research
In addition, the company provided guidance for FY23; Merck now expects worldwide sales of $57.2 billion – $58.7 billion and full-year GAAP EPS in a range of $5.86 per share – $6.01 per share.
AbbVie
Quarterly Estimates –
Analysts have been bearish in their earnings outlooks, with four negative earnings estimate revisions hitting the tape over the last several months. Still, the Zacks Consensus EPS Estimate of $3.54 suggests an improvement of nearly 7% year-over-year.
Image Source: Zacks Investment Research
The company’s top line is also estimated to expand, with our consensus sales estimate of $15.4 billion indicating an uptick of 3% from year-ago quarterly sales of $14.9 billion.
Quarterly Performance –
The company has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
In AbbVie’s latest print, the company delivered a 3% EPS surprise and reported sales roughly 0.8% below expectations.
Image Source: Zacks Investment Research
Valuation –
ABBV shares currently trade at a 12.4X forward earnings multiple, above the 9.5X five-year median by a fair margin and nearly in line with 2022 highs.
Image Source: Zacks Investment Research
Further, ABBV’s forward price-to-sales works out to be 4.8X, again above the 3.7X five-year median and the Zacks Medical sector average.
Image Source: Zacks Investment Research
ABBV carries a Style Score of “B” for Value.
Putting Everything Together
As the critically-important earnings season continues to roll on, investors have been met with quarterly results that have helped keep the market afloat. Needless to say, the so-called earnings apocalypse has yet to materialize.
Next week, AbbVie (ABBV - Free Report) is slated to unveil its quarterly results on Thursday, February 9th, before market open. We’ve already received quarterly results from a few peers, including Eli Lilly (LLY - Free Report) and Merck & Co. (MRK - Free Report) .
Analysts have lowered their earnings outlooks for AbbVie’s quarter to be reported, with estimates indicating Y/Y increases in earnings and revenue.
In addition, the company’s forward price-to-sales and forward earnings multiple reside well above their respective five-year medians.
Heading into the release, AbbVie is currently a Zacks Rank #3 (Hold).